CVRx Launches a new Barostim™ Programmer

Rhea-AI Summary

CVRx, Inc launches its new Barostim Programmer, enhancing programming for the Barostim therapy for heart failure. Approved by the FDA, this second-generation device incorporates a modern design, upgraded cellular capabilities, and a user-friendly interface, facilitating easier programming of implantable pulse generators. CEO Nadim Yared emphasized the improvements in hardware and software, aimed at better customer support. The rollout across the U.S. market is scheduled throughout 2022.

Positive

• Launch of second-generation Barostim Programmer enhances customer support.
• FDA approval signifies regulatory trust and market readiness.
• Improved user interface makes therapy easier to manage.

Negative

• None.

The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S. Food and Drug Administration (FDA) earlier this year.

The second-generation programmer has a modernized design, operates on an upgraded cellular network that enables remote view access, and includes an improved user interface that simplifies implantable pulse generator (IPG) programming. The new Barostim Programmer is compatible with all Barostim implantable systems.

"The new Barostim Programmer builds upon the earlier model and includes significant enhancements to both hardware and software," said Nadim Yared, President and CEO of CVRx. "This upgrade allows CVRx to continue to provide superior customer support and reflects our commitment to innovating across all aspects of Barostim therapy."

A complete rollout of the new Barostim Programmer is planned across the U.S. market throughout 2022.

About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Media Contact:
Erich Sandoval
Finn Partners
917.497.2867 
erich.sandoval@finnpartners.com 

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443.213.0501
ir@cvrx.com

FAQ

What is the new Barostim Programmer from CVRx?

The Barostim Programmer is a second-generation device designed to simplify the programming of Barostim therapy for heart failure.

When was the new Barostim Programmer approved by the FDA?

The new Barostim Programmer was approved by the FDA earlier in 2022.

How does the Barostim Programmer improve customer support?

It enables remote view access and has an upgraded user interface, enhancing ease of use.

What are the benefits of the Barostim therapy?

Barostim therapy helps improve symptoms of heart failure by delivering electrical pulses to baroreceptors.

Is the Barostim Programmer available across the U.S.?

Yes, a complete rollout of the new Barostim Programmer is planned across the U.S. throughout 2022.